[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-001", "question": "A 45-year-old man with a history of alcoholic cirrhosis presents to the ICU with massive upper gastrointestinal bleeding. Despite endoscopic intervention and octreotide infusion, bleeding persists, and he develops hemodynamic instability. Transjugular intrahepatic portosystemic shunt (TIPS) is considered, but imaging reveals a rare anatomical variant. What is the most appropriate next step in management?", "options": ["Proceed with TIPS using a covered stent to mitigate risks", "Initiate balloon tamponade with a Sengstaken-Blakemore tube", "Administer terlipressin as an alternative vasoconstrictor", "Perform urgent surgical portocaval shunt", "Refer for angiographic embolization of the coronary vein"], "answer": "E", "answer_index": 4, "explanation": "In persistent variceal bleeding with anatomical variants precluding TIPS, angiographic embolization targets specific bleeding vessels like the coronary vein, offering a less invasive option. TIPS is contraindicated due to the variant, while surgical shunts carry high mortality in unstable patients. Terlipressin and balloon tamponade are temporizing but not definitive here.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "The patient has massive upper gastrointestinal bleeding secondary to alcoholic cirrhosis, refractory to initial medical and endoscopic interventions. Transjugular intrahepatic portosystemic shunt (TIPS) is being considered but is precluded by a rare anatomical variant. The patient is hemodynamically unstable.\n\nLet's analyze the options:\nA. Proceed with TIPS using a covered stent to mitigate risks: The question explicitly states that imaging reveals an anatomical variant that prevents TIPS. Therefore, proceeding with TIPS is not appropriate.\n\nB. Initiate balloon tamponade with a Sengstaken-Blakemore tube: Balloon tamponade is an effective temporizing measure for acute variceal bleeding when other methods fail and definitive treatment is pending or not immediately available. Given the patient's hemodynamic instability and refractory bleeding, this could be a reasonable immediate step to stabilize the patient. However, it is not a definitive treatment.\n\nC. Administer terlipressin as an alternative vasoconstrictor: Terlipressin is a pharmacological agent used to reduce portal pressure in variceal bleeding. The patient is already on octreotide, and the bleeding is massive and refractory, suggesting that medical management alone may not be sufficient. While terlipressin could be added, it is unlikely to be the *single best next step* for refractory, hemodynamically unstable bleeding when procedural options are available.\n\nD. Perform urgent surgical portocaval shunt: Surgical shunts are definitive treatments for variceal bleeding but are major procedures with significant morbidity and mortality in patients with advanced cirrhosis. They are typically considered when less invasive options like TIPS or interventional radiology procedures are not feasible or have failed.\n\nE. Refer for angiographic embolization of the coronary vein: The coronary vein (gastric coronary vein) is a major feeding vessel for gastric varices, which commonly occur in alcoholic cirrhosis and can cause massive bleeding. Angiographic embolization is a highly effective interventional radiology procedure for controlling active variceal bleeding, particularly gastric varices, when TIPS is not an option. It targets the bleeding source directly and is generally less invasive than emergent surgery. Given that TIPS is contraindicated, embolization represents a logical next step to control the bleeding, especially if the anatomical variant does not preclude access for this procedure.\n\nComparing options B and E: Balloon tamponade is a temporizing measure, whereas embolization offers a more definitive treatment for the bleeding source. In a hemodynamically unstable patient with refractory bleeding where TIPS is not an option, a definitive or highly effective interventional procedure is generally preferred over purely temporizing measures, provided it is feasible.\n\nThe final answer is $\\boxed{E}$."}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-002", "question": "A 62-year-old woman with metastatic breast cancer on paclitaxel develops acute dyspnea and hypoxemia. CT angiography shows no pulmonary embolism, but echocardiography reveals right ventricular strain. Bone marrow biopsy confirms tumor infiltration. What is the most likely diagnosis?", "options": ["Paclitaxel-induced pneumonitis", "Tumor microembolism syndrome", "Lymphangitic carcinomatosis", "Chemotherapy-associated pulmonary veno-occlusive disease", "Metastatic tumor thrombus in pulmonary arteries"], "answer": "B", "answer_index": 1, "explanation": "Tumor microembolism syndrome occurs when tumor cells embolize to pulmonary vasculature, causing right heart strain without macroscopic emboli, fitting this presentation in metastatic cancer. Lymphangitic carcinomatosis typically shows interstitial patterns on imaging, while paclitaxel pneumonitis is inflammatory. Veno-occlusive disease is more associated with stem cell transplant regimens.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with acute dyspnea and hypoxemia in the context of metastatic breast cancer on paclitaxel. The absence of pulmonary embolism on CT angiography is important. Echocardiography reveals right ventricular strain, indicating pulmonary hypertension. Bone marrow biopsy confirms tumor infiltration, suggesting widespread metastatic disease.\n\nLet's analyze the options:\n\nA. Paclitaxel-induced pneumonitis: While paclitaxel can cause pneumonitis leading to dyspnea and hypoxemia, it does not typically cause significant acute pulmonary hypertension and right ventricular strain as a primary mechanism, unless the hypoxemia is extremely severe.\n\nB. Tumor microembolism syndrome: This syndrome occurs when tumor cells or fragments embolize to the pulmonary vasculature, leading to diffuse microvascular obstruction. This obstruction causes increased pulmonary vascular resistance, pulmonary hypertension, and subsequently right ventricular strain and failure. The absence of detectable embolism on CT angiography is consistent with *micro*emboli, which are too small of a size to be visualized. Widespread tumor infiltration (suggested by bone marrow biopsy) supports the presence of circulating tumor cells or fragments. This diagnosis explains all the clinical findings: metastatic cancer, acute dyspnea, hypoxemia, pulmonary hypertension, and RV strain, with negative CT for larger emboli.\n\nC. Lymphangitic carcinomatosis: This involves tumor spread through the lymphatics of the lungs. It causes dyspnea and hypoxemia due to impaired gas exchange and lymphatic obstruction. Pulmonary hypertension and RV strain can occur in severe or advanced cases, but it's not the most direct or primary cause of acute RV strain compared to direct vascular obstruction.\n\nD. Chemotherapy-associated pulmonary veno-occlusive disease: While some chemotherapies can cause PVOD, paclitaxel is not a common or well-established agent for inducing this condition, especially compared to agents like busulfan. PVOD does cause pulmonary hypertension and RV strain.\n\nE. Metastatic tumor thrombus in pulmonary arteries: This implies larger intravascular tumor emboli within the pulmonary arteries. While this can cause pulmonary hypertension and RV strain, smaller, non-visualized microemboli are more consistent with the negative CT scan for PE and the potential for circulating tumor cells from widespread infiltration. Tumor microembolism syndrome is a more encompassing term for diffuse microvascular obstruction by tumor.\n\nConsidering the combination of metastatic cancer, acute dyspnea, hypoxemia, absence of visible PE on CT, and significant RV strain, tumor microembolism syndrome is the most likely diagnosis that explains the widespread microvascular obstruction leading to pulmonary hypertension and right heart strain.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-003", "question": "A 28-year-old man presents to the emergency department with severe headache, vomiting, and photophobia after a recent hiking trip. CSF analysis shows lymphocytic pleocytosis, elevated protein, and normal glucose. PCR for common viruses is negative, but serology reveals antibodies to a rare pathogen. What is the most appropriate initial management?", "options": ["Intravenous acyclovir for presumed herpes encephalitis", "Empiric antibiotics for bacterial meningitis", "Supportive care with close monitoring", "Corticosteroids to reduce inflammation", "Antifungal therapy targeting endemic mycoses"], "answer": "C", "answer_index": 2, "explanation": "This presentation suggests lymphocytic meningitis from a rare arbovirus like Jamestown Canyon virus, where supportive care is the mainstay as no specific antiviral exists. Acyclovir is for herpes, unnecessary here with negative PCR. Antibiotics are for bacterial etiologies, ruled out by CSF profile.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "The patient presents with symptoms suggestive of meningitis or encephalitis (severe headache, vomiting, photophobia).\n\nThe CSF analysis shows:\n*   Lymphocytic pleocytosis: This suggests viral, fungal, tuberculous, or certain chronic bacterial meningitides, or non-infectious inflammatory processes. It makes acute bacterial meningitis less likely.\n*   Elevated protein: Nonspecific, but common in inflammatory conditions of the CNS.\n*   Normal glucose: This makes typical bacterial or fungal meningitis less likely, as glucose is often low in those conditions. It is consistent with viral meningitis/encephalitis, neuroborreliosis (Lyme disease), or some other causes.\n\nThe patient's history of a recent hiking trip is a crucial epidemiological clue pointing towards potential exposure to pathogens found in the environment, such as tick-borne or mosquito-borne viruses, Lyme disease bacteria, or endemic fungi.\n\nPCR for common viruses being negative helps rule out the most frequent viral culprits like enteroviruses, HSV, and VZV, but does not exclude all viral causes.\n\nThe key piece of information is that serology reveals antibodies to a \"rare pathogen.\" This implies that a specific diagnostic test has identified a particular agent, which is considered rare. The management should be guided by this specific identification, provided a treatment option is available among the choices.\n\nLet's evaluate the options:\nA.  Intravenous acyclovir for presumed herpes encephalitis: While HSV encephalitis can present with similar CSF findings, the negative PCR for common viruses and the discovery of antibodies to a \"rare pathogen\" make HSV less likely compared to a truly rare entity.\nB.  Empiric antibiotics for bacterial meningitis: The CSF profile (lymphocytic pleocytosis, normal glucose) makes typical acute bacterial meningitis unlikely, so empiric antibiotics are not the most appropriate initial management.\nC.  Supportive care with close monitoring: This is always part of management, but if a specific treatable pathogen is identified, specific therapy is usually preferred over solely supportive care.\nD.  Corticosteroids to reduce inflammation: Corticosteroids are typically not the first-line management for suspected infectious meningoencephalitis and might even be detrimental in some cases. They are usually reserved for specific situations like severe cerebral edema or certain non-infectious inflammatory conditions.\nE.  Antifungal therapy targeting endemic mycoses: Endemic mycoses (e.g., *Coccidioides immitis*, *Histoplasma capsulatum*, *Blastomyces dermatitidis*) can be acquired through inhalation during outdoor activities like hiking, especially in endemic geographic areas. They can cause meningitis with a lymphocytic pleocytosis and normal glucose. Serology is often used for their diagnosis. If the \"rare pathogen\" identified by serology is indeed an endemic fungus, then antifungal therapy would be the most appropriate initial management.\n\nConsidering that serology has identified a specific, albeit rare, pathogen, and that endemic mycoses fit the clinical and epidemiological context (hiking exposure, CSF profile), leading to a specific treatment option (antifungal therapy), option E stands out as the most appropriate initial management. For example, if serology identified *Coccidioides*, treatment with fluconazole would be indicated.\n\nThe final answer is $\\boxed{E}$."}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-004", "question": "A 7-year-old boy with autism spectrum disorder presents with recurrent episodes of staring spells and facial twitching. EEG shows multifocal epileptiform discharges, and MRI reveals subtle cortical dysplasia. Genetic testing identifies a de novo mutation. What is the most effective first-line therapy?", "options": ["Valproic acid for broad-spectrum coverage", "Levetiracetam to minimize behavioral side effects", "Carbamazepine for focal seizures", "Vagus nerve stimulation as adjunct", "Ketogenic diet initiation"], "answer": "B", "answer_index": 1, "explanation": "In epileptic encephalopathy due to mutations like SCN8A, levetiracetam is preferred for its efficacy and lower risk of exacerbating behavioral issues in autism. Valproic acid can worsen aggression, while carbamazepine may aggravate generalized features. Dietary therapies are second-line.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "NOT FOR CLINICAL USE.\nThe patient is a 7-year-old boy with autism spectrum disorder (ASD) presenting with symptoms suggestive of epilepsy. The EEG shows multifocal epileptiform discharges, indicating that the seizures may be generalized or originate from multiple cortical areas. The presence of ASD and a de novo mutation suggests a potentially complex underlying etiology for his epilepsy.\n\nWe need to select the most effective *first-line* therapy from the given options.\n\nA. Valproic acid is a broad-spectrum antiepileptic drug (AED) effective for various seizure types, including generalized and focal seizures. It is a common first-line choice when the seizure type is not definitively focal or if generalized epilepsy is suspected.\n\nB. Levetiracetam is also a broad-spectrum AED with efficacy against focal and generalized seizures. It is frequently used as a first-line agent, especially in children. A significant advantage of levetiracetam, and the reason is explicitly mentioned in the option, is its relatively favorable neuropsychiatric and cognitive side effect profile, particularly in patients with developmental disorders like ASD. While some behavioral side effects like irritability can occur, it is often considered to cause fewer cognitive and behavioral disturbances compared to other AEDs, and can sometimes even improve behavior.\n\nC. Carbamazepine is primarily indicated for focal-onset seizures. Given the multifocal epileptiform discharges on EEG and staring spells (which can be indicative of absence seizures or complex focal seizures), carbamazepine might not be the most appropriate first-line choice, as it can be ineffective or even worsen certain seizure types like absence or myoclonic seizures. It can also cause behavioral side effects.\n\nD. Vagus nerve stimulation (VNS) is a surgical intervention typically used as an adjunctive therapy for patients with epilepsy that is refractory to multiple AEDs. It is not a first-line treatment.\n\nE. The ketogenic diet is a highly effective dietary therapy for epilepsy, particularly in children, but it is generally considered when first-line AEDs have failed to control seizures or for specific epilepsy syndromes known to respond well to the diet. It is not typically the initial pharmacological approach.\n\nConsidering the multifocal nature of the epilepsy and the presence of ASD, choosing an AED with a favorable behavioral and cognitive profile is crucial. Levetiracetam's established efficacy as a broad-spectrum AED alongside its generally better tolerability regarding behavior and cognition in this population makes it the most appropriate first-line choice among the given options. The rationale provided in option B directly addresses this critical consideration.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-005", "question": "A 55-year-old man with Parkinson's disease develops sudden onset of dysarthria and hemiparesis. MRI shows acute infarction in the lenticulostriate territory, but vessel imaging is normal. Coagulation studies reveal an abnormality. What is the underlying mechanism?", "options": ["Cardioembolic stroke from atrial fibrillation", "Lacunar infarct due to small vessel disease", "Thrombotic stroke from antiphospholipid syndrome", "Vasculitis mimicking stroke", "Embolic stroke from levodopa-induced arrhythmia"], "answer": "C", "answer_index": 2, "explanation": "Antiphospholipid syndrome can cause thrombotic strokes in atypical territories without large vessel occlusion, especially with coagulation abnormalities. Lacunar infarcts are typically hypertensive, not matching this profile. Cardioembolism usually involves larger territories or arrhythmias, absent here.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient presents with sudden onset neurological deficits (dysarthria and hemiparesis), which are classic signs of a stroke. The MRI confirms an acute infarction in the lenticulostriate territory, which supplies the basal ganglia and internal capsule. Vessel imaging is normal, suggesting no large vessel atherosclerosis or occlusion is the primary cause. The crucial piece of information is that \"coagulation studies reveal an abnormality.\"\n\nLet's analyze the options in light of these findings:\n\nA. Cardioembolic stroke from atrial fibrillation: Atrial fibrillation can lead to emboli causing stroke. While Parkinson's disease patients have a higher risk of AF, AF itself does not typically cause a primary abnormality on standard coagulation tests (PT, PTT, INR).\n\nB. Lacunar infarct due to small vessel disease: Infarcts in the lenticulostriate territory are often lacunar and caused by small vessel disease (e.g., arteriolosclerosis). This is a common mechanism for stroke in patients with risk factors like hypertension, diabetes, or aging. However, small vessel disease itself is a pathological process of the vessel walls, not typically identified by an abnormality in routine coagulation studies.\n\nC. Thrombotic stroke from antiphospholipid syndrome (APS): Antiphospholipid syndrome is an autoimmune disorder characterized by a hypercoagulable state that can lead to arterial and venous thrombosis. Thromboses can occur in medium-sized and small arteries, including the lenticulostriate arteries, causing stroke. The diagnosis of APS is based on the presence of specific antiphospholipid antibodies detected through laboratory tests (lupus anticoagulant, anticardiolipin antibodies, anti-beta-2 glycoprotein I antibodies). These tests fall under comprehensive coagulation or thrombophilia studies, and their positivity constitutes an \"abnormality in coagulation studies\" that predisposes to thrombosis. This option best explains all the findings, especially the abnormal coagulation studies.\n\nD. Vasculitis mimicking stroke: Vasculitis can cause stroke by inflammation and occlusion of blood vessels. While it can affect small vessels, its primary finding is inflammation of the vessel wall, often associated with elevated inflammatory markers. Routine coagulation studies (PT, PTT, etc.) are not typically considered abnormal in vasculitis unless there are secondary complications.\n\nE. Embolic stroke from levodopa-induced arrhythmia: Levodopa can rarely cause arrhythmias that might lead to emboli. However, an arrhythmia and its resulting embolism do not directly cause an abnormality in coagulation studies.\n\nConsidering that the MRI shows infarction in the lenticulostriate territory and vessel imaging is normal (implying no large vessel disease), and crucially, that coagulation studies reveal an abnormality, Antiphospholipid Syndrome (APS) is the most fitting diagnosis. APS is a prothrombotic state directly identified by specific abnormalities in coagulation-related antibody tests, which can lead to thrombosis in penetrating arteries and cause strokes.\n\nThe answer is (C)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-006", "question": "In the ICU, a 70-year-old patient with septic shock from pneumonia remains hypotensive despite vasopressors and fluids. Adrenal function testing shows a blunted cortisol response, but random cortisol is normal. What is the next step in management?", "options": ["Initiate hydrocortisone replacement therapy", "Add fludrocortisone for mineralocorticoid support", "Perform cosyntropin stimulation test", "Switch to alternative vasopressor like vasopressin", "Administer ascorbic acid and thiamine"], "answer": "D", "answer_index": 3, "explanation": "Relative adrenal insufficiency in sepsis may not respond to steroids if cortisol is normal; switching to vasopressin addresses vasoplegia more effectively. Hydrocortisone is controversial without clear deficiency. Cosyntropin is already implied by blunted response.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient is in septic shock refractory to fluids and vasopressors, and adrenal function testing shows a blunted cortisol response with a normal random cortisol. This scenario strongly suggests critical illness-related corticosteroid insufficiency (CIRCI), where the adrenal glands cannot mount an adequate cortisol response to the severe stress of septic shock, even if baseline cortisol levels appear normal.\n\nIn patients with septic shock refractory to adequate fluid resuscitation and vasopressors, empirical administration of low-dose corticosteroids is recommended to improve hemodynamic status and potentially reduce mortality. The finding of a \"blunted cortisol response\" on adrenal function testing, despite a normal random cortisol, supports the indication for corticosteroid therapy. A blunted response, typically seen on a cosyntropin stimulation test (e.g., peak cortisol < 18-20 mcg/dL or an absolute rise < 9 mcg/dL), indicates that the adrenal gland is not responding appropriately to ACTH stimulation, which is crucial in stress states.\n\nLet's analyze the options:\nA. Initiate hydrocortisone replacement therapy: This directly addresses the suspected adrenal insufficiency contributing to refractory shock. Hydrocortisone provides both glucocorticoid and mineralocorticoid effects and is the standard treatment in this setting. This is a management intervention.\nB. Add fludrocortisone for mineralocorticoid support: While hydrocortisone has mineralocorticoid effects, pure mineralocorticoid deficiency is less common in septic shock. Adding fludrocortisone would be considered if mineralocorticoid deficiency is specifically identified or if glucocorticoid therapy alone is insufficient, but it's not the primary next step for suspected general adrenal insufficiency in septic shock.\nC. Perform cosyntropin stimulation test: While this is the gold standard diagnostic test for adrenal insufficiency, the question states that \"Adrenal function testing shows a blunted cortisol response\". This implies a test has already been done and yielded suggestive results. In established refractory septic shock, delaying treatment to perform further diagnostic tests, when symptoms strongly suggest the need for intervention, may be detrimental. Empirical treatment is often initiated based on clinical suspicion and preliminary test findings in life-threatening conditions.\nD. Switch to alternative vasopressor like vasopressin: Vasopressin can be a useful adjunct or alternative vasopressor in refractory septic shock, but it does not address the potential underlying adrenal insufficiency which, if present, would also contribute to the hypotension.\nE. Administer ascorbic acid and thiamine: These are sometimes used as adjunctive therapies in septic shock, but they are not the primary intervention for suspected adrenal insufficiency.\n\nGiven the refractory nature of the shock and the evidence of blunted adrenal response, the most appropriate next step in management is to try and restore adequate cortisol levels with replacement therapy.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-007", "question": "A 38-year-old woman with chronic myeloid leukemia on dasatinib develops pleural effusions and fatigue. Cytogenetic analysis shows additional clonal evolution. What is the most appropriate therapeutic adjustment?", "options": ["Switch to imatinib to reduce pulmonary toxicity", "Add interferon-alpha for immunomodulation", "Initiate ponatinib for resistant mutations", "Dose reduce dasatinib and monitor", "Proceed to allogeneic stem cell transplant"], "answer": "C", "answer_index": 2, "explanation": "Clonal evolution in CML on dasatinib often indicates T315I mutation, for which ponatinib is effective despite pulmonary risks. Imatinib lacks potency against advanced disease. Transplant is considered but not first-line without failure of second-generation TKIs.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "NOT FOR CLINICAL USE.\nThe patient has chronic myeloid leukemia (CML) treated with dasatinib. She presents with pleural effusions and fatigue, along with evidence of additional clonal evolution on cytogenetic analysis.\n\nPleural effusions are a known side effect of dasatinib. However, the presence of \"additional clonal evolution\" is a critical finding. Clonal evolution in CML signifies the acquisition of new genetic abnormalities in the leukemia cells, which typically leads to resistance to tyrosine kinase inhibitors (TKIs) and/or indicates progression to a more aggressive phase of the disease.\n\nLet's evaluate the options:\nA. Switch to imatinib to reduce pulmonary toxicity: Imatinib is a first-generation TKI, generally less potent than dasatinib. Switching to imatinib might inadequately control the disease if resistance has developed, and it does not directly address the clonal evolution.\n\nB. Add interferon-alpha for immunomodulation: Interferon-alpha is an older treatment for CML, largely replaced by TKIs. Adding it to a contemporary TKI regimen for managing resistance is not standard practice.\n\nC. Initiate ponatinib for resistant mutations: Ponatinib is a third-generation TKI that is highly potent and effective against a wide range of BCR-ABL mutations, including T315I, which confers resistance to other TKIs. Clonal evolution strongly suggests the development of resistance mechanisms or progression requiring a more potent TKI. Ponatinib is the most appropriate choice when resistance to other TKIs is suspected or confirmed.\n\nD. Dose reduce dasatinib and monitor: While dose reduction is a strategy to manage side effects like pleural effusions attributed solely to dasatinib toxicity, it does not address the underlying problem of clonal evolution and potential resistance. If the disease is evolving, reducing the dose of the current TKI may lead to further progression.\n\nE. Proceed to allogeneic stem cell transplant: Allogeneic stem cell transplant (allo-SCT) is a curative option but is a high-risk procedure. It is typically considered for patients with highly advanced disease, resistance to multiple TKIs, or when TKIs are contraindicated or ineffective. Initiating a more potent TKI like ponatinib is generally considered before resorting to transplant, especially when only one TKI (dasatinib) has been used or failed and there is evidence of resistance.\n\nGiven the significant finding of clonal evolution, the most appropriate therapeutic adjustment is to address the likely resistance to dasatinib. Ponatinib is specifically indicated for TKI-resistant CML.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-008", "question": "A 35-year-old woman in the emergency department collapses after ingesting an unknown substance. She has bradycardia, hypotension, and miosis. Atropine provides partial response, but symptoms recur. What is the definitive antidote?", "options": ["Pralidoxime for organophosphate poisoning", "N-acetylcysteine for acetaminophen", "Flumazenil for benzodiazepine overdose", "Physostigmine for anticholinergic toxicity", "Hydroxocobalamin for cyanide"], "answer": "A", "answer_index": 0, "explanation": "This cholinergic toxidrome suggests organophosphate poisoning, where pralidoxime regenerates acetylcholinesterase after initial atropine. Atropine alone is insufficient for severe cases. Other antidotes target different mechanisms not fitting the presentation.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient presents with bradycardia, hypotension, and miosis. These symptoms are characteristic of cholinergic excess, often seen in poisoning with organophosphates, carbamates, or certain mushrooms, or due to muscarinic agonists. The patient collapsing implies a severe presentation.\n\nAtropine is an anticholinergic agent that blocks the effects of acetylcholine at muscarinic receptors. It would be expected to counteract symptoms like bradycardia, miosis, and excessive secretions. The fact that atropine provides only a partial response and symptoms recur suggests that the underlying cause of cholinergic excess is not fully managed by muscarinic blockade alone, or that the toxic agent is causing ongoing inhibition of acetylcholinesterase, leading to continued acetylcholine accumulation.\n\nLet's evaluate the options:\nA. Pralidoxime for organophosphate poisoning: Organophosphates inhibit acetylcholinesterase (AChE), leading to a buildup of acetylcholine. This causes both muscarinic and nicotinic symptoms. Pralidoxime (2-PAM) is an AChE reactivator that specifically targets organophosphate poisoning. It is considered the definitive antidote because it can restore AChE activity. Atropine is used to manage muscarinic symptoms, but pralidoxime addresses the underlying enzyme inhibition. The partial and recurring response to atropine is highly suggestive of organophosphate poisoning, where the enzyme inhibition is a persistent problem until reactivated.\n\nB. N-acetylcysteine for acetaminophen: Acetaminophen overdose causes hepatic toxicity, with symptoms typically appearing hours to days later. It does not cause bradycardia, hypotension, and miosis acutely.\n\nC. Flumazenil for benzodiazepine overdose: Benzodiazepine overdose causes central nervous system depression (sedation, respiratory depression). Miosis is not a typical feature, and bradycardia/hypotension are not primary effects.\n\nD. Physostigmine for anticholinergic toxicity: Anticholinergic toxicity presents with opposite symptoms to cholinergic excess (tachycardia, hypertension, mydriasis, dry skin, delirium). Physostigmine is an AChE inhibitor and would worsen anticholinergic symptoms; it is used to treat anticholinergic toxicity. The patient's symptoms are cholinergic, not anticholinergic.\n\nE. Hydroxocobalamin for cyanide: Cyanide poisoning causes cellular hypoxia. While it can lead to cardiovascular collapse, miosis is not a hallmark symptom.\n\nBased on the classic cholinergic symptoms (bradycardia, hypotension, miosis) and the partial/recurrent response to atropine, organophosphate poisoning is the most likely diagnosis. Pralidoxime is the definitive antidote for organophosphate poisoning as it reactivates inhibited acetylcholinesterase.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-009", "question": "A 12-year-old girl with juvenile idiopathic arthritis on etanercept develops fever, rash, and lymphadenopathy. Serology is positive for a virus, but PCR on lymph node biopsy reveals clonal T-cell population. What is the most likely complication?", "options": ["Drug reaction with eosinophilia and systemic symptoms", "EBV-associated lymphoproliferative disorder", "Macrophage activation syndrome", "Secondary hemophagocytic lymphohistiocytosis", "TNF inhibitor-induced lymphoma"], "answer": "E", "answer_index": 4, "explanation": "TNF inhibitors like etanercept increase risk of T-cell lymphomas, especially with clonal populations on biopsy, beyond viral associations. EBV-LPD is B-cell predominant. MAS and HLH are cytokine-driven without clonality.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "NOT FOR CLINICAL USE.\n\nThe patient is a 12-year-old girl with juvenile idiopathic arthritis on etanercept, a TNF-alpha inhibitor. She presents with fever, rash, and lymphadenopathy. Serology is positive for a virus, and lymph node biopsy reveals a clonal T-cell population.\n\nLet's analyze the options:\nA.  Drug reaction with eosinophilia and systemic symptoms (DRESS): DRESS is a hypersensitivity reaction causing fever, rash, eosinophilia, and organ involvement. It typically does not involve a clonal T-cell population.\nB.  EBV-associated lymphoproliferative disorder (LPD): TNF inhibitors can impair immune surveillance, increasing the risk of opportunistic infections and lymphoproliferative disorders, particularly those associated with Epstein-Barr virus (EBV). Fever, rash, and lymphadenopathy are common symptoms. The presence of a clonal T-cell population is a hallmark of LPD. Given the positive viral serology and the patient's immunosuppressed state, EBV is the most common viral culprit associated with LPD in this context, making this a strong contender.\nC.  Macrophage activation syndrome (MAS): MAS is a severe systemic inflammatory complication that can occur in JIA. While it shares some symptoms like fever and rash, it is characterized by dysregulated macrophage activation and is not primarily defined by a clonal T-cell population.\nD.  Secondary hemophagocytic lymphohistiocytosis (sHLH): Similar to MAS, sHLH is a hyperinflammatory syndrome. While viral infections can trigger sHLH, the finding of a clonal T-cell population suggests a lymphoid neoplastic or pre-neoplastic process rather than a primary hyperinflammatory cascade.\nE.  TNF inhibitor-induced lymphoma: TNF inhibitors are associated with an increased risk of lymphoma. A clonal T-cell population found on lymph node biopsy is indicative of lymphoma. This is a plausible diagnosis, but option B is more specific if the virus implicated is EBV, as EBV plays a direct oncogenic role in LPDs.\n\nThe finding of a clonal T-cell population is critical and points directly towards a lymphoproliferative disorder or lymphoma. The positive viral serology, in the context of immunosuppression from etanercept and lymphadenopathy, strongly suggests a viral-driven process. EBV is the most common virus associated with lymphoproliferative disorders in immunocompromised individuals. Therefore, an EBV-associated lymphoproliferative disorder is the most likely specific complication that explains all the findings. While EBV-associated LPD can progress to or be classified as lymphoma, option B provides a more specific etiological explanation given the viral serology.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-010", "question": "A 68-year-old man with amyotrophic lateral sclerosis presents with progressive dysphagia and aspiration. Videofluoroscopy shows pharyngeal weakness. Non-invasive ventilation is in use. What is the most appropriate intervention?", "options": ["Percutaneous endoscopic gastrostomy placement", "Botulinum toxin injection into cricopharyngeus", "Tracheostomy for airway protection", "Speech therapy with swallowing exercises", "Pharmacologic enhancement with edrophonium"], "answer": "B", "answer_index": 1, "explanation": "In ALS with cricopharyngeal dysfunction causing dysphagia, botulinum toxin relaxes the muscle to improve swallowing, a targeted approach before invasive feeding. PEG is for nutrition but not dysphagia mechanism. Tracheostomy addresses ventilation, not swallowing.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "A 68-year-old man with amyotrophic lateral sclerosis (ALS) presents with progressive dysphagia and aspiration, with videofluoroscopy showing pharyngeal weakness. Non-invasive ventilation is in use.\n\nLet's analyze the options:\nA. Percutaneous endoscopic gastrostomy (PEG) placement: This provides a safe route for nutrition and hydration, bypassing the compromised swallowing mechanism. Given the progressive dysphagia and aspiration, malnutrition and dehydration are significant risks, and aspiration can lead to pneumonia. PEG is a standard intervention in ALS patients with significant swallowing difficulties to ensure adequate nutritional intake and reduce aspiration.\n\nB. Botulinum toxin injection into cricopharyngeus: This intervention is typically used for cricopharyngeal achalasia or spasm, which impairs the opening of the cricopharyngeus muscle, hindering the passage of food from the pharynx to the esophagus. The videofluoroscopy shows pharyngeal weakness, not necessarily cricopharyngeal spasm. Therefore, this is less likely to be the most appropriate intervention for generalized pharyngeal weakness.\n\nC. Tracheostomy for airway protection: Tracheostomy can be considered for airway protection in severe cases of aspiration or respiratory failure. However, the patient is already on non-invasive ventilation, which addresses respiratory support. While airway protection is a concern with aspiration, a tracheostomy does not directly fix the swallowing dysfunction itself and is a more invasive procedure. PEG is typically prioritized for nutritional and hydration support in dysphagia.\n\nD. Speech therapy with swallowing exercises: Speech therapy can be beneficial in managing dysphagia by teaching compensatory strategies and performing exercises. However, ALS is a progressive neuromuscular disease. As pharyngeal weakness progresses due to muscle degeneration, compensatory strategies and exercises may become insufficient to ensure safe swallowing and prevent aspiration. While often used in conjunction with other interventions, it may not be the single *most* appropriate intervention when significant aspiration is occurring.\n\nE. Pharmacologic enhancement with edrophonium: Edrophonium is a cholinesterase inhibitor used in the management of myasthenia gravis. ALS is a motor neuron disease and is not responsive to cholinesterase inhibitors; edrophonium is therefore inappropriate and ineffective in this condition.\n\nConsidering the progressive nature of ALS and the presence of dysphagia and aspiration due to pharyngeal weakness, the most critical intervention to ensure adequate nutrition, hydration, and prevent serious complications like aspiration pneumonia is to provide a safe means of feeding. A PEG tube directly addresses this need by bypassing the dysfunctional swallowing mechanism.\n\nThe answer is (A)"}]